Printer Friendly

MEDIMMUNE'S CEO REVIEWS RECENT DEVELOPMENTS

 MEDIMMUNE'S CEO REVIEWS RECENT DEVELOPMENTS
 GAITHERSBURG, Md., May 7 /PRNewswire/ -- At MedImmune Inc.'s annual


meeting of shareholders today in Gaithersburg, Md., Dr. Wayne T. Hockmeyer, president and chief executive officer, reviewed the company's progress in 1991 and first quarter 1992 and the status of the company's product development programs. The annual meeting was the company's first since its initial public offering on May 9, 1991.
 Dr. Hockmeyer said that, "The Phase II/III prophylaxis clinical trial for Hypermune-RSV(TM), the company's immune globulin for the prevention and treatment of respiratory syncytial virus, was completed in April and MedImmune anticipates filing a product license application with the FDA in September 1992. Preclinical studies for pre- and post- exposure prophylaxis of HIV infection are continuing on MEDI-488, the company's broadly-reactive HIV human monoclonal antibody, with the first chimpanzee studies expected to begin later this month. MedImmune is completing preclinical studies on its B-19 Parvovirus vaccine and anticipates filing an IND with the FDA in the second half of 1992. In addition, MedImmune expects to conclude preclinical studies on its BCG- Lyme disease vaccine during the second half of 1992.
 "Following scheduled product deliveries in the second quarter of 1992, MedImmune does not expect to ship any additional CytoGam(TM) to its distributor this year. This is a result of reduced 1992 sales expectations from the distributor because of increased competition from off-label use of anti-viral drugs for prevention of CMV disease in transplant patients. The company expects to file with the FDA in the second quarter an amendment to the PLA seeking approval for use of CytoGam(TM) in all solid organ transplants. MedImmune also recently commenced a Phase I clinical trial for CytoGam(TM) to prevent CMV disease in AIDS patients."
 Dr. Hockmeyer added that, "Preclinical studies of the company's BCG- AIDS vaccine, which MedImmune is conducting under terms of its agreement with Merck & Co. continue to progress, as does work under the company's separate program with Merck aimed at the development of AIDS immunotherapeutic products."
 During 1991, MedImmune had total revenues of $14 million, including $5.6 million from the first year of sales of CytoGam(TM) to the company's distributor. Net earnings of $1.6 million represented the company's first profitable year after only three full years of operations.
 Dr. Hockmeyer concluded by stating that, "MedImmune remains committed to achieving its objectives of profitability for 1992 as the company continues its research and product development programs."
 MedImmune, Inc. was founded in 1988 to develop, manufacture and market therapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company's corporate headquarters are located in Gaithersburg, Md.
 -0- 5/7/92
 /CONTACT: David Wright or David Mott of MedImmune, 301-417-0770, or Fredric Spar of Kekst and Company, 212-593-2655, for MedImmune/
 (MEDI) CO: MedImmune Inc. ST: Maryland IN: MTC SU:


KD -- NY042 -- 7519 05/07/92 10:24 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 7, 1992
Words:482
Previous Article:KMART CORPORATION REPORTS APRIL SALES INCREASE
Next Article:AMERICAN EXPLORATION APPOINTS HAROLD KORELL SENIOR VICE PRESIDENT-PRODUCTION
Topics:


Related Articles
MEDIMMUNE ANNOUNCES REVIEW OF MEDI 488 RESEARCH PROGRAM
MEDIMMUNE CHAIRMAN, CEO NAMED REGIONAL ENTREPRENEUR OF THE YEAR; WAYNE T. HOCKMEYER HONORED FOR CONTRIBUTIONS IN THE LIFE SCIENCES FIELD
MEDIMMUNE AND CYANAMID TO ENTER FOUR DRUG, $30 MILLION STRATEGIC ALLIANCE
MEDIMMUNE TO ACQUIRE MELVILLE BIOLOGICS FROM THE NEW YORK BLOOD CENTER FOR $40 MILLION
MEDIMMUNE AND NEW YORK BLOOD CENTER ANNOUNCE FILING WITH FDA FOR MARKETING APPROVAL OF INTRAVENOUS IMMUNE GLOBULIN PRODUCT
BIOTRANSPLANT AND MEDIMMUNE BEGIN PHASE I/II TRIAL OF BTI-322 FOR THE REVERSAL OF ORGAN TRANSPLANT REJECTION
MedImmune Sponsors AACR Fellowship Grant for Research on Biologics-Based Cancer Therapies.
MedImmune Licenses Elusys Therapeutics' Technology for Use in Developing New Therapies Targeting Infectious Disease.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters